SCHEMBL6296549

SCHEMBL6296549

CCOC(=O)C1=C(C(F)(F)F)Nc2n[nH]cc2C1c1cccs1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.45
ALDH1A1 P00352 8/20 0.44
ADORA2B P29275 4/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 7/20 0.44
HPGD P15428 2/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
AGTR1 P30556 1/20 0.43
MAPT P10636 4/20 0.43
MEN1 O00255 2/20 0.43
ADORA3 P0DMS8 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ACHE P22303 3/20 0.42
CACNA1D Q01668 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7433891 0.85 L3MBTL1 (0.35) ALDH1A1KMT2AKDM4EHPGDHSD17B10
SCHEMBL9726304 0.85 ALDH1A1 (0.54) PKMALDH1A1ADORA2BKMT2AKDM4E
SCHEMBL6292278 0.83 ADORA3 (0.47) ALDH1A1ADORA2BKDM4ETSHRMAPT
SCHEMBL6296588 0.82 ADORA2B (0.58) ALDH1A1ADORA2BKDM4EHPGDTSHR
SCHEMBL6297236 0.82 MEN1 (0.44) ALDH1A1ADORA2BKMT2ATSHRMEN1
SCHEMBL6293656 0.82 CACNA1C (0.52) ACHECACNA1D
SCHEMBL6293604 0.81 EGFR (0.42) ALDH1A1ADORA2BKDM4EHPGDTSHR
SCHEMBL6296647 0.80 GAA (0.49) ALDH1A1KMT2AKDM4ETSHRLMNA
SCHEMBL6293641 0.80 ABCC1 (0.53) ALDH1A1ADORA2BKMT2AKDM4EHPGD
SCHEMBL6296612 0.79 MAPT (0.48) PKMADORA2BKMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 US disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 US disclosed
EP-1355909-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-10-29 EP disclosed
WO-2002062795-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB PKM 196/4885ALDH1A1 944/4885ADORA2B 2541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.